Últimas noticias sobre I-MAB (NASDAQ:IMAB) Bolsa

I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

Lands' End (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LE#NASDAQ">LE</a>) reported quarterly losses of $(0.18) per share which met the analyst consensus estimate. This is a 10 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $261.21 million which missed the analyst consensus estimate of $272.60 million by 4.18 percent. This is a 8.50 percent decrease over sales of $285.47 million the same period last year.

Earnings

Earnings Misses

News

Lands' End Q1 Adj. EPS $(0.18), Inline, Sales $261.21M Miss $272.60M Estimate

APP rises over 15 points in the session
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04230651/Screenshot-2025-06-04-at-7.04.06%E2%80%AFPM-1015x1024.png" alt="" class="wp-image-13890" /></figure>
Applovin Corp. (APP) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:03 AM on June 4th, a significant trading signal occurred for Applovin Corp. (APP) as it demonstrated a Power Inflow at a price of $401.10. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Applovin's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Applovin's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for APP, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025</a>, which are responsible for parts of the data within this article.
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved
After Market Close, UPDATE: The price at the time of the Power Inflow was $401.10. The returns on the High price ($417.43) and Close price ($416.43) after the Power Inflow are respectively 4.1% and 3.8%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Past Results are Not Indicative of Future Results
.

Equities

Technicals

Opinion

Signals

Trading Ideas

AppLovin Stock Rises 4.1% After Key Trading Signal

TD Securities analyst Andrew Charles maintains Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) with a Buy and raises the price target from $330 to $400.

Price Target

Analyst Ratings

WING

TD Securities Maintains Buy on Wingstop, Raises Price Target to $400

<ul>
<li>Record Eurobonds ADV of $2.9 Billion on 116% Increase in Block Trading and 500% Increase in Portfolio Trading ADV</li>
</ul>
Client-Initiated
<ul>
<li>Strong increases in block trading ADV across U.S. credit (+41%), emerging markets (+24%) and eurobonds (+116%). We launched our targeted block trading solution in U.S. credit in mid-May.
<ul>
<li>Block trading in emerging markets and eurobonds both benefitted from the launch of our targeted block solution in late 2024, which has generated cumulative trading volume of approximately $1.7 billion and $2.7 billion,respectively,since launch.</li>
</ul>
</li>
<li>Clients continued to leverage our algos in U.S. government bond trading, helping to drive a 57% increase in ADV to $28.3 billion with estimated market share of 2.6% in May.</li>
</ul>
Portfolio Trading
<ul>
<li>Year-to-date May 2025, estimated market share of U.S. credit portfolio trading is 18.6%, compared to 14.1% in the prior year same period, an increase of approximately 450 basis points.2
<ul>
<li>90% of all portfolio trading ADV was executed over X-Pro in May.</li>
</ul>
</li>
</ul>
Dealer-Initiated
<ul>
<li>Dealer-initiated ADV increased 41% to $1.8 billion.</li>
</ul>

General

MKTX

MarketAxess Announces Trading Volume Statistics For May 2025 With 44% Increase in Total ADV Driven by 22% Increase in Total Credit ADV and 59% Increase in Total Rates ADV

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) sharp rise to an all-time high of $111,800 has entered a decisive phase, as data from Glassnode reveals intensified profit-taking <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45652549/vice-president-jd-vance-predicts-100m-bitcoin-holders-the-us-ought-to-be-leaning-into-bitcoin">by long-term holders</a>.
What Happened: The surge, initially driven by aggressive spot buying, is now encountering persistent sell pressure from earlier market participants, posing a critical test of the market's resilience.
Glassnode's on-chain analysis <a href="https://insights.glassnode.com/the-week-onchain-week-22-2025/?utm_campaign=WoC_22_25&amp;utm_medium=email&amp;utm_source=newsletter">released</a> on Thursday shows that key support levels at $103,700 and $95,600 will likely determine whether bullish momentum can be sustained.
"With key support at $103.7k and $95.6k, and signs of older investors offloading, the bulls now face a critical test of their resolve," the report states.
While the current cycle has delivered multiple high-profit waves, the latest realized profits peaked at $1.47 billion per day, marking the fifth major sell event of this rally. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45775027/pump-funs-1b-token-plan-risks-undermining-solana-defi-fueling-meme-coin-scams-experts-warn">Pump.fun&#8217;s $1B Token Plan Risks Undermining Solana DeFi, Fueling Meme Coin Scams, Experts Warn</a>
Notably, the majority of this selling is being led by investors holding Bitcoin for over a year, indicating that this is not driven by speculative short-term traders but by conviction-led capital rotation.
Historical accumulation zones, previously demand-heavy, have flipped into active distribution zones, particularly among holders who bought in the $25K–$31K and $60K–$73K ranges. 
Why It Matters: The shift signals a deeper market rotation, where seasoned holders are choosing to de-risk rather than bet on further upside.
Cost basis and statistical models further highlight $103,700 and $95,600 as critical supports. 
A breakdown below these levels, particularly without a strong demand-side catalyst, could indicate broader trend exhaustion. 
Meanwhile, the resistance ceiling remains at $114,800.
Short-term holder behavior also plays a role. The average cost basis for recent buyers sits at $97,100. If Bitcoin trades below this threshold for an extended period, it could challenge bullish sentiment among newer participants.
Glassnode also notes that the profit-taking behavior has become more measured compared to prior bull cycles. While still intense, this regime suggests maturing investor psychology and decreasing speculative excess. 
The current cycle shows lower realized profit as a percentage of market cap compared to previous tops, reinforcing the idea of more structured capital flows.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45772954/can-bitcoin-boost-portfolio-returns-without-increasing-risk-bitwises-matt-hougan-says-it-can">Can Bitcoin Boost Portfolio Returns Without Increasing Risk? Bitwise&#8217;s Matt Hougan Says It Can</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Bull Run On The Brink As Long-Term Holders Accelerate Profit-Taking: Report

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4443060-1&amp;h=4233216002&amp;u=https%3A%2F%2Fimux.com%2F&amp;a=Immunic%2C+Inc.">Immunic, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>),&nbsp;a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced the completion of enrollment for both phase 3 ENSURE trials of lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with relapsing multiple sclerosis and additional phase 2 CALLIPER trial data in patients with progressive multiple sclerosis underlining the recently released positive top-line results.
Additional Data Available from Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis (PMS)
Building on the recently released data showing reductions in the relative risk of 24-week confirmed disability worsening (24wCDW) events based on the Expanded Disability Status Scale (EDSS) at the end of the main treatment period, newly available data for the secondary endpoint of time to 24wCDW based on the EDSS further reinforces the neuroprotective potential of vidofludimus calcium. In the overall PMS patient population (n=467), vidofludimus calcium demonstrated a clinically meaningful reduction of the hazard ratio (HR) for 24wCDW by 24% compared to placebo (HR 0.76). Further analyses by disease subtype showed that vidofludimus calcium was associated with a 33% reduction in 24wCDW in the primary progressive multiple sclerosis (PPMS) study population (n=152) compared to placebo (HR 0.67), a 19% reduction in the non-active secondary progressive multiple sclerosis (naSPMS) study population (n=268) compared to placebo (HR 0.81), and a 34% reduction in the active secondary progressive multiple sclerosis (aSPMS) study population (n=47) compared to placebo (HR 0.66).
Similarly, consistent with the recent top-line data, further analyses of subpopulations – both with and without inflammatory gadolinium-enhanced lesion activity at baseline, who are largely shown to not benefit from current anti-inflammatory therapies – continued to demonstrate promising results. For the overall population, vidofludimus calcium reduced 24wCDW in patients without evidence of gadolinium-enhancing lesions at baseline by 34% compared to placebo (HR 0.66). Encouraging results were likewise observed for the PPMS (reduction in 24wCDW: 35%; HR 0.65) and naSPMS (reduction in 24wCDW: 30%; HR 0.70) study populations compared to placebo.

IMUX

Immunic Announces Addl Data From Phase 2 CALLIPER Trial In Progressive MS, Supporting Recently Released Top-Line Results and Underlining Vidofludimus Calcium's Neuroprotective Potential

Needham analyst Mike Cikos reiterates MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Buy and maintains $270 price target.

Reiteration

Needham Reiterates Buy on MongoDB, Maintains $270 Price Target

WestPark Capital analyst Casey Ryan reiterates CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) from Hold to Hold.

CRWD

WestPark Capital Reiterates Hold on CrowdStrike Holdingsto Hold

Updated 2025 Guidance
Vermilion is adjusting its 2025 capital budget to a range of $630 to $660 million, reflecting a reduction of approximately $100 million from the mid-point of our previous capital budget range of $730 to $760 million. This reduction reflects the removal of all remaining E&amp;D capital associated with the Saskatchewan and United States divested assets post-closing. Vermilion expects full year and second half 2025 production to range between 117,000 to 122,000 boe/d, 68% natural gas-weighted in the second half of 2025. On a go-forward basis, it is estimated that over 90% of production will come from our global gas portfolio and over 80% of capital is expected be allocated to these assets. Vermilion will continue to evaluate capital investment levels during this period of increased volatility and will adjust capital if necessary to prioritize free cash flow over production growth during 2025 and 2026.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Category</td>
<td colspan="1" rowspan="1">
Original
2025 Guidance&#x2A;
</td>
<td colspan="1" rowspan="1">
Post-Westbrick
2025 Guidance&#x2A;
</td>
<td colspan="1" rowspan="1">
Updated&nbsp;
2025 Guidance&#x2A;
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Production (boe/d)</td>
<td colspan="1" rowspan="1">84,000 – 88,000</td>
<td colspan="1" rowspan="1">125,000 – 130,000</td>
<td colspan="1" rowspan="1">117,000 – 122,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">% Natural Gas</td>
<td colspan="1" rowspan="1">56&nbsp;%</td>
<td colspan="1" rowspan="1">62&nbsp;%</td>
<td colspan="1" rowspan="1">65&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">E&amp;D capital expenditures ($MM)</td>
<td colspan="1" rowspan="1">$600 – 625</td>
<td colspan="1" rowspan="1">$730 – 760</td>
<td colspan="1" rowspan="1">$630 – 660</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Royalty rate (% of sales)</td>
<td colspan="1" rowspan="1">8 – 10%</td>
<td colspan="1" rowspan="1">9 – 11%</td>
<td colspan="1" rowspan="1">8 – 10%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating ($/boe)</td>
<td colspan="1" rowspan="1">$17.00 – 18.00</td>
<td colspan="1" rowspan="1">$13.50 – 14.50</td>
<td colspan="1" rowspan="1">$13.00 – 14.00</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Transportation ($/boe)</td>
<td colspan="1" rowspan="1">$3.50 – 4.00</td>
<td colspan="1" rowspan="1">$3.00 – 3.50</td>
<td colspan="1" rowspan="1">$3.00 – 3.50</td>
</tr>
<tr>
<td colspan="1" rowspan="1">General and administration ($/boe)&#x2A;&#x2A;</td>
<td colspan="1" rowspan="1">$2.75 – 3.25</td>
<td colspan="1" rowspan="1">$2.25 – 2.75</td>
<td colspan="1" rowspan="1">$2.25 – 2.75</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cash taxes (% of pre-tax FFO)</td>
<td colspan="1" rowspan="1">7 – 9%</td>
<td colspan="1" rowspan="1">6 – 10%</td>
<td colspan="1" rowspan="1">4 – 8%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Asset retirement obligations settled ($MM)</td>
<td colspan="1" rowspan="1">$60</td>
<td colspan="1" rowspan="1">$60</td>
<td colspan="1" rowspan="1">$60</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Payments on lease obligations ($MM)</td>
<td colspan="1" rowspan="1">$20</td>
<td colspan="1" rowspan="1">$20</td>
<td colspan="1" rowspan="1">$15</td>
</tr>
</tbody>
</table>
</figure>

Guidance

Commodities

Markets

Vermilion Energy Adjusts 2025 Capital Budget To $630M-$660M, Reflecting A Reduction Of Approximately $100M From The Mid-point Of Previous Capital Budget Of $730M-$760M

Contracts

IperionX On Wednesday Announced Award Of U.S. Department Of Defense SBIR Phase III Contract For Up To $99M

– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 –
– Additional Data from Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Further Supports the Recently Released Positive Top-Line Results and Further Underlines Vidofludimus Calcium's Neuroprotective Potential –
– New CALLIPER Data Regarding Time to 24-Week Confirmed Disability Worsening Shows Substantial and Medically Relevant Reductions for Vidofludimus Calcium Over Placebo in the Overall Study Population and Major Disease Subtypes –
NEW YORK, June 5, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4443060-1&amp;h=4233216002&amp;u=https%3A%2F%2Fimux.com%2F&amp;a=Immunic%2C+Inc.">Immunic, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>),&nbsp;a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced the completion of enrollment for both phase 3 ENSURE trials of lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with relapsing multiple sclerosis and additional phase 2 CALLIPER trial data in patients with progressive multiple sclerosis underlining the recently released positive top-line results.
Enrollment Completed for Both Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis (RMS)
The ENSURE program comprises two identical multicenter, randomized, double-blind phase 3 trials designed to evaluate the efficacy, safety and tolerability of vidofludimus calcium versus placebo in RMS patients. Each of the trials, titled ENSURE-1 and ENSURE-2, enrolled adult patients with active RMS at more than 100 sites in 15 countries, including the United States, India and countries in the Middle East and North Africa (MENA) region, Latin America, and Central and Eastern Europe. In total, 1,121 patients in ENSURE-1 and 1,100 patients in ENSURE-2 have been randomized in a double-blinded fashion to either 30 mg daily doses of vidofludimus calcium or placebo. The primary endpoint for both trials is time to first relapse up to 72 weeks. Secondary endpoints include time to confirmed disability worsening based on the Expanded Disability Status Scale (EDSS), volume of new T2-lesions, time to sustained clinically relevant changes in cognition, and magnetic resonance imaging (MRI)-based endpoints.

Immunic Completes Enrollment For Both Phase 3 ENSURE Trials Of Vidofludimus Calcium In Relapsing Multiple Sclerosis; Top-Line Data Expected End Of 2026

<ul>
<li>$177 million in total consideration subject to customary fees and adjustments</li>
<li>Industrial, utility and data center power demand is increasing globally</li>
<li>B&amp;W now well-capitalized and poised to leverage growth in 2025 and beyond</li>
</ul>

B&W Announces Sale Of Diamond Power To ANDRITZ For $177M , Eyes Growth In Data Center And Utility Markets

Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>) with a Buy and raises the price target from $11 to $11.5.

RNXT

Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $11.5

Life Time Group Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTH#NYSE">LTH</a>) ("Life Time" or the "Company") announced today that certain affiliates of Leonard Green &amp; Partners, L.P. and TPG Inc. (the "Selling Stockholders") intend to offer and sell 20,000,000 shares of the Company's common stock in an underwritten public offering pursuant to Life Time's shelf registration statement filed with the Securities and Exchange Commission (the "SEC"). The Selling Stockholders will receive all of the proceeds from the proposed offering. The Company will not receive any of the proceeds from the sale of shares of the Company's common stock by the Selling Stockholders. Following the consummation of the offering, the Company's voting group, which includes the Selling Stockholders, will hold approximately 43.1% of the Company's common stock.

Offerings

Life Time Shareholders Leonard Green, TPG to Sell 20M Shares in Public Offering

Net proceeds from the Transaction will be directed towards debt repayment to further accelerate deleveraging efforts and strengthen Vermilion's balance sheet. Based on current strip commodity pricing(1) and operational plans, we would expect to exit 2025 with net debt(2) of $1.3 billion, with a trailing net debt to FFO ratio(3) of 1.3 times.
The Assets consist of approximately 5,500 boe/d (81% oil and liquids) of production and approximately 10 mmboe of Proved Developed Producing reserves estimated as evaluated by McDaniel &amp; Associates Consultants Ltd. at December 31, 2024. The Transaction has an effective date of January 1, 2025 and is anticipated to close in Q3 2025, subject to the satisfaction of other customary closing conditions. The Transaction agreement includes $10 million of contingent payments(4) based on WTI prices over the two-year period starting July 1, 2025.
This Transaction, combined with the sale of our East Finn assets in 2023, completes our exit from the United States, allowing us to focus on our core gas-weighted assets in Canada and Europe. Vermilion would like to sincerely thank our talented and dedicated field teams in Wyoming for their commitment to safe and efficient operations over the past 11 years as well as the technical teams, which provided support from Denver and Calgary.

Vermilion Energy Agrees To Sell Its United States Assets For $120M

Wallbox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBX#NYSE">WBX</a>), a global leader in electric vehicle (EV) charging and energy management solutions, today announced two recent private placements of the Company's Class A ordinary shares for an aggregate of $15 million. The first is an investment of more than $9 million from the Government of Spain through the Spanish Society for Technological Transformation (SETT), which joins Wallbox's shareholder base as part of the Company's financing round from February 2025. Additionally, existing investors including Inversiones Financieras Perseo, S.L. (a subsidiary of Iberdrola), Orilla Asset Management, S.L., Wallbox CEO and Cofounder Enric Asunción, and others contributed more than $5 million through a second investment, reaffirming their continued support for Wallbox's growth and technological leadership.
The Spanish Society for Technological Transformation (SETT), a state-owned enterprise under the Ministry for Digital Transformatión and Public Administration, is a public entity dedicated to financing and promoting advanced and transformative technologies. With this investment, SETT supports Wallbox's leadership as a technological frontrunner in the energy transition.
This investment by SETT is made through the Next Tech initiative, which aims to encourage private investment and improve access to financing in strategic sectors of the Spanish economy through disruptive technologies. Next Tech is part of the Recovery, Transformation, and Resilience Plan and is one of the key instruments managed by SETT. In addition, SETT oversees two other financial tools designed to strengthen Spain's technological business ecosystem: PERTE Chip, focused on microelectronics and semiconductors, and the Spain Audiovisual Hub, which supports the digitalization and growth of the audiovisual sector.
These investments strengthen Wallbox's balance sheet and provide the resources to accelerate the global adoption of its EV charging solutions, advance the digitalization of its solutions, and drive the development of cutting-edge technologies for smarter, more efficient energy management.

Wallbox Secures $15M Investment, Including $9M From Spanish Government to Boost EV Tech

Ascendiant Capital analyst Edward Woo maintains Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) with a Buy and raises the price target from $11 to $11.5.

Ascendiant Capital Maintains Buy on Myomo, Raises Price Target to $11.5

On Wednesday, June 4, U.S. markets closed mixed, as weak services and job data highlighted the toll of Trump&#8217;s policy uncertainty. The S&amp;P 500 was flat, the Nasdaq edged up, and the Dow dipped.
Investors weighed trade tensions, softening policy stances, and corporate earnings. Tesla and CrowdStrike fell, while HPE and GlobalFoundries gained. Trading volume remained light.
According to the economic data, the ISM services PMI fell to 49.9 in May, missing expectations, while private businesses added just 37K jobs, down from 60K in April.
Most S&amp;P 500 sectors rose Wednesday, led by communication services, materials, and real estate, while energy and utilities declined.
The Dow closed lower by 0.22% at 42,427.74, the S&amp;P 500 gained 0.01% to 5,970.81, and the Nasdaq rose 0.32% to 19,460.49.
<h2 class="wp-block-heading">Asia Markets Today</h2>
On Thursday, Japan&#8217;s Nikkei 225 closed 0.57% lower at 37,532.50, led by losses in the Paper &amp; Pulp, Transport and Communication sectors.
Australia&#8217; S&amp;P/ASX 200 slid 0.03%, ending the session at 8,538.90, led by losses in the Gold, Healthcare, and Utilities sectors.
India&#8217;s Nifty 50 was up 0.53% at 24,757.80, and the Nifty 500 rose 0.56% to 22,934.50.
China&#8217;s Shanghai Composite was up 0.23% at 3,384.10, and Shanghai Shenzhen CSI 300 gained 0.23% to 3,877.56.
Hong Kong&#8217;s Hang Seng closed the session 1.07% higher at 23,906.97.
<h2 class="wp-block-heading">Eurozone at 05:45 AM ET</h2>
The European STOXX 50 index was up 0.42%.
Germany&#8217;s DAX index gained 0.44%.
France&#8217;s CAC 40 rose 0.50%.
U.K.&#8217;s FTSE 100 index traded higher by 0.27%.
<h2 class="wp-block-heading">Commodities at 05:45 AM ET</h2>
Crude Oil WTI was trading higher by 0.29% at $63.01/bbl, and Brent was up 0.32% at $65.07/bbl.
Oil prices steadied after a 1% drop, pressured by rising U.S. fuel stockpiles, Saudi price cuts for Asia, soft demand signals, and weak global economic data.
Natural gas slid 0.57% to $3.695.
Gold traded higher by 0.49% to $3,416.17, Silver rose 3.19% to $35.753, and Copper rose 2.29% to $4.9968.
<h2 class="wp-block-heading">U.S. Futures at 05:45 AM ET</h2>
Dow Jones futures rose 0.11%, S&amp;P 500 gained 0.05%, and Nasdaq 100 was up 0.05%.
<h2 class="wp-block-heading">Forex at 05:45 AM ET</h2>
The U.S. Dollar Index slid 0.04% to 98.78, USD/JPY was up 0.24% to 143.10, and USD/AUD fell 0.33% to 1.5353.
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Markets Mixed, Europe Gains, Gold Inches Toward All Time High - Global Markets Today While US Slept

Economist Craig Shapiro argues that the debt ceiling, a mechanism only used by the U.S. and Denmark, fails to curb excessive government spending and instead creates political theater every few years.
What Happened: Shapiro, who is a macro strategist at the Bear Traps Report highlights the Federal Reserve's role, noting its consistent interventions in the bond market.
According to him, these interventions, which include providing liquidity during market hiccups, have enabled Washington's unchecked spending by ensuring stable market function for U.S. Treasuries.
The Fed's actions, Shapiro contends, remove market discipline, as Congress and administrations rely on the Fed to backstop their fiscal policies, a dynamic he says has fueled deficit spending.
Recent data support this concern as the U.S. federal debt has nearly tripled since 2009, with the Treasury Department frequently hitting the congressionally mandated borrowing limit, according to the Council on Foreign Relations.
Shapiro suggests that if the Fed stepped back and allowed "bond vigilantes"—investors who sell bonds to protest fiscal policy, raising borrowing costs—to act, market forces could pressure Washington to curb spending, a tactic seen in emerging markets with unsustainable deficits.
&#8220;Ending it is probably a good thing but really won&#8217;t stop the spending in DC,&#8221; says Shapiro.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The debt ceiling prevents nothing. Only two countries in the world have a debt ceiling. The US and Denmark All it does is create a circus every few years as one party tries to hold up incessant spending by the other party in power, playing games with the USA credit rating as…
&mdash; Craig Shapiro (@ces921) <a href="https://twitter.com/ces921/status/1930390505390780869?ref_src=twsrc%5Etfw">June 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/45786854/magnificent-7-drive-54-of-market-cap-gains-in-sp-500-since-april-lows-the-market-cannot-survive-without-big-tech">Magnificent 7 Drive 54% Of Market Cap Gains In S&amp;P 500 Since April Lows: &#8216;The Market Cannot Survive Without Big Tech&#8217; </a>
Why It Matters: Without the debt ceiling, Shapiro warns, the Fed's role as an enabler must be addressed to impose real fiscal discipline on Washington.
Current Fed policy adds complexity, with the federal funds rate held at 4.25% to 4.50% in May 2025, and markets expecting two 0.25% rate cuts by year-end.
As of the publication of this article, the 10-year Treasury bond yielded 4.35% and the two-year bond was at 3.87%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 95.6% likelihood of the Federal Reserve keeping the current interest rates unchanged in its June meeting.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Thursday. The SPY was up 0.099% at $596.52, while the QQQ advanced 0.093% to $529.26, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45764818/bill-ackman-urges-end-to-fannie-mae-freddie-mac-conservatorship-says-will-enable-them-to-operate-more-successfully-and-efficiently" target="_blank" rel="noreferrer noopener">Bill Ackman Urges End To Fannie Mae, Freddie Mac Conservatorship: Says Will Enable Them To ‘Operate More Successfully And Efficiently&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. 
Photo courtesy: RozenskiP / Shutterstock.com

Federal Reserve

Debt Ceiling: How The Fed Fuels Washington's Spending Spree, 'Ending It Is Probably A Good Thing,' Says Expert

<a href="https://www.reuters.com/world/india/walmarts-flipkart-secures-approval-direct-lending-india-documents-show-2025-06-05/" title="https://www.reuters.com/world/india/walmarts-flipkart-secures-approval-direct-lending-india-documents-show-2025-06-05/">https://www.reuters.com/world/india/walmarts-flipkart-secures-approval-direct-lending-india-documents-show-2025-06-05/</a>

Comments

I-MAB

Noticias

Últimas noticias sobre I-MAB (NASDAQ:IMAB) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL